(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 16.8% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Aquestive Therapeutics's revenue in 2024 is $51,502,000.On average, 6 Wall Street analysts forecast AQST's revenue for 2024 to be $4,621,571,077, with the lowest AQST revenue forecast at $4,497,303,481, and the highest AQST revenue forecast at $4,743,107,517. On average, 5 Wall Street analysts forecast AQST's revenue for 2025 to be $5,283,512,243, with the lowest AQST revenue forecast at $4,533,718,894, and the highest AQST revenue forecast at $5,644,388,984.
In 2026, AQST is forecast to generate $7,865,273,972 in revenue, with the lowest revenue forecast at $6,827,889,900 and the highest revenue forecast at $8,865,332,246.